These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 31906998)

  • 1. Definitive chemoradiotherapy in patients with squamous cell cancers of the head and neck - results from an unselected cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Schüttrumpf L; Marschner S; Scheu K; Hess J; Rietzler S; Walch A; Baumeister P; Kirchner T; Ganswindt U; Zitzelsberger H; Belka C; Maihoefer C
    Radiat Oncol; 2020 Jan; 15(1):7. PubMed ID: 31906998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Postoperative (chemo) radiation in patients with squamous cell cancers of the head and neck - clinical results from the cohort of the clinical cooperation group "Personalized Radiotherapy in Head and Neck Cancer".
    Maihoefer C; Schüttrumpf L; Macht C; Pflugradt U; Hess J; Schneider L; Woischke C; Walch A; Baumeister P; Kirchner T; Zitzelsberger H; Belka C; Ganswindt U
    Radiat Oncol; 2018 Jul; 13(1):123. PubMed ID: 29970111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary tumor volume is an important predictor of clinical outcomes among patients with locally advanced squamous cell cancer of the head and neck treated with definitive chemoradiotherapy.
    Strongin A; Yovino S; Taylor R; Wolf J; Cullen K; Zimrin A; Strome S; Regine W; Suntharalingam M
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1823-30. PubMed ID: 21549516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
    Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
    Trials; 2014 Nov; 15():469. PubMed ID: 25432788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A prospective, multicenter DAHANCA study of hyperfractionated, accelerated radiotherapy for head and neck squamous cell carcinoma.
    Saksø M; Andersen E; Bentzen J; Andersen M; Johansen J; Primdahl H; Overgaard J; Eriksen JG
    Acta Oncol; 2019 Oct; 58(10):1495-1501. PubMed ID: 31519130
    [No Abstract]   [Full Text] [Related]  

  • 7. Salvage surgery for advanced stage head and neck squamous cell carcinoma following radiotherapy or chemoradiation.
    Elbers JBW; Veldhuis LI; Bhairosing PA; Smeele LE; Jóźwiak K; van den Brekel MWM; Verheij M; Al-Mamgani A; Zuur CL
    Eur Arch Otorhinolaryngol; 2019 Mar; 276(3):647-655. PubMed ID: 30673847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cisplatin Every 3 Weeks Versus Weekly With Definitive Concurrent Radiotherapy for Squamous Cell Carcinoma of the Head and Neck.
    Bauml JM; Vinnakota R; Anna Park YH; Bates SE; Fojo T; Aggarwal C; Limaye S; Damjanov N; Di Stefano J; Ciunci C; Genden EM; Wisnivesky JP; Ferrandino R; Mamtani R; Langer CJ; Cohen RB; Sigel K
    J Natl Cancer Inst; 2019 May; 111(5):490-497. PubMed ID: 30239887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival outcomes for head and neck cancer patients with N3 cervical nodal metastases.
    Virk JS; Ingle M; Podesta CM; Gujral DM; Awad Z
    Clin Otolaryngol; 2020 May; 45(3):342-349. PubMed ID: 31869000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating Adjuvant Therapy With Chemoradiation vs Radiation Alone for Patients With HPV-Negative N2a Head and Neck Cancer.
    Yan F; Li H; Kaczmar JM; Sharma AK; Day TA; Neskey DM; Pipkorn P; Zenga J; Graboyes EM
    JAMA Otolaryngol Head Neck Surg; 2020 Dec; 146(12):1109-1119. PubMed ID: 32790830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of upfront neck dissection in definitive radiotherapy for locally advanced hypopharyngeal squamous cell carcinoma: A single-center retrospective analysis.
    Katano A; Yamashita H; Saito Y; Kobayashi K
    Head Neck; 2024 Nov; 46(11):2815-2823. PubMed ID: 38842032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of chemotherapy regimen on treatment outcomes in patients with HPV-associated oropharyngeal cancer with T4 disease treated with definitive concurrent chemoradiation.
    Bhattasali O; Ryoo JJ; Thompson LDR; Abdalla IA; Chen J; Iganej S
    Oral Oncol; 2019 Aug; 95():74-78. PubMed ID: 31345397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer-derived copy number alterations signatures are prognostic in chemoradiotherapy-treated head and neck squamous cell carcinoma.
    Essers PBM; van der Heijden M; Vossen D; de Roest RH; Leemans CR; Brakenhoff RH; van den Brekel MWM; Bartelink H; Verheij M; Vens C
    Int J Cancer; 2020 Sep; 147(6):1732-1739. PubMed ID: 32167160
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of salvage surgery for recurrent or residual head and neck squamous cell carcinoma.
    Maruo T; Zenda S; Shinozaki T; Tomioka T; Okano W; Sakuraba M; Tahara M; Hayashi R
    Jpn J Clin Oncol; 2020 Mar; 50(3):288-295. PubMed ID: 31845736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The importance of adjuvant treatment and primary anatomical site in head and neck basaloid squamous cell carcinoma survival: an analysis of the National Cancer Database.
    Gootee J; Patel M; Aurit S; Silberstein P
    Clin Transl Oncol; 2020 Dec; 22(12):2264-2274. PubMed ID: 32440914
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor volume as a predictive parameter in the sequential therapy (induction chemotherapy) of head and neck squamous cell carcinomas.
    Bohlen M; Busch C-; Sehner S; Forterre F; Bier J; Berliner C; Bußmann L; Münscher A
    Eur Arch Otorhinolaryngol; 2019 Apr; 276(4):1183-1189. PubMed ID: 30725209
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic impact of pathological complete remission after preoperative irradiation in patients with locally advanced head and neck squamous cell carcinoma: re-analysis of a phase 3 clinical study.
    Wang K; Yi J; Huang X; Qu Y; Luo J; Xiao J; Zhang S; Tang Y; Liu W; Xu G; Gao L; Xu Z; Liu S; Wang X
    Radiat Oncol; 2019 Dec; 14(1):225. PubMed ID: 31831042
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lymph node ratio as a prognostic factor in head and neck cancer patients.
    Chen CC; Lin JC; Chen KW
    Radiat Oncol; 2015 Aug; 10():181. PubMed ID: 26302761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.